Myriad Genetics (MYGN) Non-Current Deferred Tax Liability: 2014-2023
Historic Non-Current Deferred Tax Liability for Myriad Genetics (MYGN) over the last 10 years, with Sep 2023 value amounting to $2.7 million.
- Myriad Genetics' Non-Current Deferred Tax Liability fell 74.29% to $2.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.7 million, marking a year-over-year decrease of 74.29%. This contributed to the annual value of $3.5 million for FY2022, which is 97.28% down from last year.
- Myriad Genetics' Non-Current Deferred Tax Liability amounted to $2.7 million in Q3 2023, which was down 27.03% from $3.7 million recorded in Q2 2023.
- In the past 5 years, Myriad Genetics' Non-Current Deferred Tax Liability ranged from a high of $174.3 million in Q4 2020 and a low of $2.7 million during Q3 2023.
- Over the past 3 years, Myriad Genetics' median Non-Current Deferred Tax Liability value was $23.3 million (recorded in 2022), while the average stood at $33.1 million.
- Per our database at Business Quant, Myriad Genetics' Non-Current Deferred Tax Liability surged by 130.86% in 2020 and then slumped by 97.28% in 2022.
- Quarterly analysis of 5 years shows Myriad Genetics' Non-Current Deferred Tax Liability stood at $75.5 million in 2019, then skyrocketed by 130.86% to $174.3 million in 2020, then dropped by 26.22% to $128.6 million in 2021, then slumped by 97.28% to $3.5 million in 2022, then plummeted by 74.29% to $2.7 million in 2023.
- Its Non-Current Deferred Tax Liability stands at $2.7 million for Q3 2023, versus $3.7 million for Q2 2023 and $4.1 million for Q1 2023.